Biogen and UCB’s lupus drug reached sustained remission in more patients. Why the real test is still two years away
New Phase 3 analyses strengthen dapirolizumab’s lupus profile, but Biogen and UCB still need PHOENYCS FLY to confirm efficacy.
Pharma & Biotech
Pharma & Biotech
Eisai is about to reveal five years of lecanemab treatment data, but will long-term therapy justify its benefits and risks?
Eisai will present five-year lecanemab and real-world Alzheimer's data at CTAD 2026. Explore the key efficacy and safety questions.
Pharma & Biotech
Can salanersen help Biogen defend its rare neurology franchise beyond Spinraza?
Find out how Biogen’s salanersen could reshape spinal muscular atrophy treatment after FDA breakthrough therapy status.
Pharma & Biotech
Leqembi’s sales curve just got a new number. BioArctic investors may not ignore it
Leqembi’s Alzheimer’s rollout is still slow, but Eisai’s 2028 sales simulation keeps BioArctic’s royalty story alive.
Pharma & Biotech
FDA review extension keeps Eisai and Biogen waiting on Leqembi Iqlik starting-dose strategy
Alzheimer’s drugs need easier delivery. Eisai and Biogen now face an FDA timing test that could shape Leqembi’s access story.
Pharma & Biotech
Eisai and Biogen advance injectable Alzheimer’s therapy with FDA fast-track decision
FDA fast-tracks Eisai’s LEQEMBI IQLIK for at-home Alzheimer’s care. Find out what this means for patients, payers, and delivery models today.